Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer

Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer

Introduction: For most locally advanced non–small cell lung cancer (LA-NSCLC) patients who complete definitive chemoradiotherapy (CRT) and do not experience disease progression, one year of adjuvant durvalumab is recommended. Here, we explore causes and consequences of early durvalumab discontinuati...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Michael Pennock, Balazs Halmos, William Bodner, Haiying Cheng, Rasim Gucalp, Nitin Ohri
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Elsevier 2023-07-01
Sarja:Clinical and Translational Radiation Oncology
Aiheet:
Lung cancer
Immunotherapy
Radiotherapy
Durvalumab
Toxicity
Prognosis
Linkit:http://www.sciencedirect.com/science/article/pii/S240563082300068X

Internet

http://www.sciencedirect.com/science/article/pii/S240563082300068X

Samankaltaisia teoksia